Please login to the form below

Not currently logged in
Email:
Password:

NICE backs Allergan's IBS therapy Truberzi

The £3 per day therapy was recommended in final guidance from the cost-effectiveness watchdog

AllerganNICE has recommended routine NHS funding for Allergan's Truberzi, which is the first drug for irritable bowel syndrome with diarrhoea (IBS-D) to pass through its review process.

Final guidance issued by the clinical and cost-effectiveness watchdog says the £3 per day therapy should be made available for IBS-D patients who have not responded to or cannot take other treatments.

Truberzi (eluxadoline) is the only drug licensed for IBS-D in Europe and was approved by the EMA last year based on data from two pivotal trials which revealed the drug achieved a significant improvement in two key symptoms of IBS-D - abdominal pain and diarrhoea - with relief coming in as little as a week and sustained over six months.

Eluxadoline works by stimulating to mu and kappa opioid receptors in the digestive system, and blocking delta opioid receptors, which has the effect of slowing down the movement of food through the gut. This helps to relieve associated stomach cramps and the urgency for a person to go to the toilet, according to NICE.

It is estimated that between 10-20% of the UK general population has IBS, and out of those around a third have IBS-D.

"Until now doctors have had limited options when it comes to treating IBS-D and unfortunately this has been to the detriment of patients, many of whom endure debilitating symptoms on a daily basis," said Dr Adam Farmer, consultant gastroenterologist at University Hospitals of North Midlands and scientific advisor at UK charity The IBS Network.

"For doctors to now be able to prescribe Truberzi, a targeted treatment, this will signify real change for IBS-D sufferers," he added.

NICE says Truberzi will be available for patients alongside existing drug and psychological treatments for IBS-D, such as drugs that stop spasms in the gut or hypnotherapy. It has also said Truberzi should only be offered in secondary care and must be discontinued after four weeks if the treatment is not working.

The green light from NICE is good news for Allergan, which sees Truberzi - known as Viberzi in the US - as a key component of its emerging gastrointestinal product franchise, which also includes Linzess (linaclotide) for IBS with constipation.

Viberzi sales in the US were almost $73m in the first six months of the year, almost a three-fold increase over the same period a year earlier, while Linzess contributed $315m, up 10%. Analysts have suggested sales of Viberzi/Truberzi could reach $450m by 2020.

Article by
Phil Taylor

1st September 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics